KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Non-Current Assets (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Other Non-Current Assets for 11 consecutive years, with $7.6 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 51.8% to $7.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2025, down 51.8% year-over-year, with the annual reading at $7.6 million for FY2025, 51.8% down from the prior year.
  • Other Non-Current Assets hit $7.6 million in Q4 2025 for CRISPR Therapeutics AG, down from $24.3 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $25.5 million in Q2 2025 to a low of $7.6 million in Q4 2025.
  • Historically, Other Non-Current Assets has averaged $14.0 million across 5 years, with a median of $12.0 million in 2022.
  • Biggest five-year swings in Other Non-Current Assets: soared 234.14% in 2021 and later tumbled 51.8% in 2025.
  • Year by year, Other Non-Current Assets stood at $16.9 million in 2021, then crashed by 31.21% to $11.6 million in 2022, then fell by 0.38% to $11.6 million in 2023, then soared by 36.56% to $15.8 million in 2024, then crashed by 51.8% to $7.6 million in 2025.
  • Business Quant data shows Other Non-Current Assets for CRSP at $7.6 million in Q4 2025, $24.3 million in Q3 2025, and $25.5 million in Q2 2025.